The Impact of Comorbid Diabetes Type 2 on Quality of Life in Cancer Patients Undergoing Chemotherapy

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3194275 34 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
The Impact of Comorbid Diabetes Type 2 on Quality of Life in Cancer
Patients Undergoing Chemotherapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background and Objective: Cancer and diabetes are two highly prevalent
diseases worldwide and greatly influence quality of life of those
suffering from it. The study aimed to compare quality of life in
patients diagnosed with cancer and diabetes with those without diabetes
both undergoing chemotherapy and to investigate the factors responsible
for the difference between the two groups.
Methods: A convenience sample of 101 participants who had cancer and
type 2 diabetes and 99 who had cancer without diabetes were used.
Results: Patients with comorbid diabetes were divided based on their
diabetes duration and whether they had glycaemic control or not.
Diabetic cancer patients without glycaemic control had lower scores in
global health status and in physical and emotional functioning compared
to diabetic cancer patients with glycaemic control and patients without
diabetes (p < .05). After adjusting for demographic characteristics, the
differences between the group with diabetes and without glycaemic
control and the other two groups regarding global health status were
statistically significant (p < .05). Patients with more than a 7-year
history of diabetes had a significantly lower emotional functioning than
the no diabetes group and lower global health status score than both of
the other groups (p < .05). After adjusting for clinical and demographic
characteristics, only the difference between the >= 7 years diabetes
duration group and the no diabetes groups remained significant.
Conclusion: The presence of diabetes in cancer patients who underwent
chemotherapy seems to negatively influence certain domains of quality of
life and this may be affected by the duration of diabetes and whether
glycaemic control has been achieved or not.
Έτος δημοσίευσης:
2021
Συγγραφείς:
Lavdaniti, Maria
Michalopoulou, Styliani
Owens, Dimitra-Anna and
Vlachou, Eugenia
Kazakos, Kyriakos
Περιοδικό:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Εκδότης:
BENTHAM SCIENCE PUBL LTD
Τόμος:
21
Αριθμός / τεύχος:
6
Σελίδες:
1017-1024
Λέξεις-κλειδιά:
Cancer; type 2 diabetes; chemotherapy; quality of life; Greece; factors
Επίσημο URL (Εκδότης):
DOI:
10.2174/1871530320666200729151715
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.